We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.125 | 3.85% | 3.375 | 3.00 | 3.75 | 3.50 | 2.75 | 3.00 | 2,184,986 | 12:21:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -0.75 | 3.88M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/11/2020 18:41 | Shorts been burnt teat | prof_glenglad | |
18/11/2020 12:44 | Warning Warning Overvalued Overvalued Mkt cap looks way to high. | noreply1 | |
18/11/2020 11:13 | Just need one of these to trigger some sales!!! Anything being sold in South Africa? | billthebank | |
18/11/2020 11:08 | Very good presentation and something the chav derampers can't argue against. Strong buy IMHO | hooded claw | |
18/11/2020 11:04 | Key points from the presentation.... They’ve bidded for POC and PCR kits in £22bn tender Beckman-Genedrive is for US and EUROPE. Validation is near and ‘commercial terms’ to be agreed soon after Can sell without FDA India approval ‘very very soon’ Will sell in US without Beckman too | parisv | |
18/11/2020 10:33 | well it was wash spin wash wash ... ahhh | pal44 | |
18/11/2020 09:27 | Looking forward to the presentation with DB today... 30 minutes to go... will be exciting to hear developments on the P.O.C and any potential larger deals ahead. 😁🤩 | sophisticatedtrader | |
18/11/2020 09:16 | With bonus £324k for 2019 in a loss making co is taking the pis | peanut100 | |
18/11/2020 08:58 | I am sure all this will be cleared up in one hour when the company presents to investors | isaisa1 | |
18/11/2020 08:08 | When you call me stupid maybe you should read the results are particular statement:H2 revenues significantly impacted by COVID-19 disruptionWTF!! | ammu12 | |
18/11/2020 07:58 | Are you stupid ? Stop trying to bully people and go get a life For all investors filter this dosser | jock3636 | |
18/11/2020 07:50 | Current mcap still 28m lol.At best a 5M mcap company..... | ammu12 | |
18/11/2020 07:49 | The best bit from the rns:Revenue for the year to 30 June 2020 in line with expectations at GBP1.1m (2019: GBP2.4m), with H2 revenues significantly impacted by COVID-19 disruptionI thought this was a covid share ? | ammu12 | |
17/11/2020 20:30 | Last man standing off the light please | prof_pwhite | |
17/11/2020 20:15 | COVID-19: UK records 598 more coronavirus deaths and 20,051 further cases | hodhasharon | |
17/11/2020 18:15 | WHO changed to requested further info todayWait until they start getting approvals then all the bed wetters will be buying back inIt's not his fault that approvals have taken longerBeckman Coulter tie in is also a huge opportunity once FDA approval landsGlad I do not spend much time on here its full of Nasty losers | jock3636 | |
17/11/2020 18:14 | Legal grounds ...Inciting the company was worth more than it actually is..Raising money at 85 penceRaising share price to 300 pence prior.Pod casts and Sky interviews backing this up....Encouraging private investors to buy, while dumping organised stock in to market....Case opened with FOC. | amaretto1 | |
17/11/2020 16:49 | pity, this was so promising! anybody considering buying or increasing holding should really have a stiff few of their favourite spirit! | abbynat | |
17/11/2020 16:39 | Any thoughts on whether it's GDR testing machines in care homes?No, the nearest GDR will get to care homes is when David Budd is sent there shortly.NCYT is where you really want to be....... | spqstrader | |
17/11/2020 15:51 | Amrish Puri, u lost any weight yet? Too much chole | prof_pwhite |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions